Pharmaceuticals
Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020
SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2020-11-23 08:00
5575
Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange
HONG KONG, Nov. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leader in discovery, development and commercialization of innovative cancer medicines, today announced that the company was officially listed and it's shares commenced trading on the Main Board...
2020-11-20 21:09
12832
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease
RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapy The Phase 3 study is expected to recruit up to 125 patients across approximately 40 U.S. clinical sites RHB-...
2020-11-20 21:00
5274
INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting
Interim review in newly diagnosed glioblastoma patients provides OS18 data, demonstrates immunogenicity and tolerability in a majority of patients PLYMOUTH MEETING, Pa., Nov. 20, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely de...
2020-11-20 21:00
5513
Zuellig Pharma expands cold storage warehouse capacity across key markets in Asia in preparation for COVID-19 vaccine
SINGAPORE, Nov. 20, 2020 /PRNewswire/ -- Zuellig Pharma, a leading healthcare services provider inAsia, announced that it will significantly expand its cold storage warehouse capacity in key regional markets over the next 12 months. As the largest vaccines and cold chain pharmaceutical distributo...
2020-11-20 15:31
5679
Qiming's Portfolio Company Antengene Lists on Main Board of HKEX
SHANGHAI, Nov. 20, 2020 /PRNewswire/ -- Qiming's portfolio company Antengene (SEHK: 6996) officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. The issue price isHK$18.08 per share; the stock opens at HK$ 19.6 per share, up 8.41%, with a market cap of HK$ 13.097 bi...
2020-11-20 14:22
6109
RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease
FDA clears IND application for Phase 2/3 study with RedHill's second novel COVID-19 candidate, RHB-107 (upamostat), an orally administered novel serine protease inhibitor, with demonstrated antiviral and potential tissue-protective effects The Phase 2/3 study is designed to evaluate outpatient-b...
2020-11-20 07:00
3085
Covis Group Announces Data for Ciraparantag Published in Blood, the Journal of the American Society of Hematology
Summarizes ciraparantag's expected mechanism of action, pharmacokinetic, and pharmacodynamic characteristics and its proof of concept as an anticoagulant reversal agent LUXEMBOURG and ZUG, Switzerland, Nov. 20, 2020 /PRNewswire/ -- Covis Group S.à r.l. ("Covis") today announced that data demonst...
2020-11-20 01:26
1921
RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib
Pre-scheduled independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia Enrollment in the 270-patient global Phase 2/3 COVID-19 study with opaganib is more than 50% complete ...
2020-11-19 20:21
4535
CUHK Microbiome Immunity Formula Hastens Recovery of COVID-19 Patients and Offers Hope to Boost Immunity
HONG KONG, Nov. 19, 2020 /PRNewswire/ -- Gut microbiota plays an important role in regulating immunity against infections. People who suffer from imbalance in gut microbiota (dysbiosis) are more susceptible to viral infection and other complications. An earlier study by the Faculty of Medicine of...
2020-11-19 17:13
3018
With Elekta Studio, Elekta brings complete image-guided brachytherapy workflow to a single room
VEENENDAAL, The Netherlands, Nov. 19, 2020 /PRNewswire/ -- Elekta (EKTA-B.ST) today introduced Elekta Studio with its launch of the ImagingRing, an advanced interventional CT system that revolves around the patient and enables clinicians to conduct the entire brachytherapy workflow - including ap...
2020-11-19 15:16
4099
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China
SHANGHAI and SAN FRANCISCO, Nov. 19, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and Sagimet Biosciences Inc. jointly announced today that they have completed patient enrollment in the ASC40 (TVB-2640) Phase 2 NASH trial inChina. The tr...
2020-11-19 08:30
2883
INEX Innovate's iGene Laboratory announces new personalised medicine genotyping analysis project with Eli Lilly and Company's research unit Lilly Centre for Clinical Pharmacology
SINGAPORE, Nov. 19, 2020 /PRNewswire/ -- INEX Innovate's iGene Laboratory (iGene) announced today a project withEli Lilly and Company's (NYSE: LLY) research unitLilly Centre for Clinical Pharmacology (LCCP), which conducts early phase clinical trials in healthy participants and patients inSingapo...
2020-11-19 08:00
2751
RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks
Enrollment completed in the U.S. Phase 2 study evaluating opaganib's safety and initial efficacy signal in 40 hospitalized patients with severe COVID-19 pneumonia A parallel global Phase 2/3 study with orally administered opaganib for severe COVID-19 is approximately 50% enrolled - on track to e...
2020-11-19 07:00
2610
Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH
HANGZHOU, China and SHAOXING, China, Nov. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that the board of directors of the Company (the "Board") resolved to change the use of the remaining Net Proceeds from the Global Offering. (see announcement: https://www....
2020-11-18 17:00
6733
Cipla launches 'Covi-G' for COVID-19 rapid antibody detection
MUMBAI, India, Nov. 18, 2020 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla") today announced that it signed a licensing agreement with aBelgium-based firm, Multi G for the distribution of their COVID-19 Rapid Antibody test kit, across most Emergin...
2020-11-18 16:36
3624
Regent Pacific Announces Important Commercialisation Progress On FORTACIN(TM) / SENSTEND(TM)
MAINLAND CHINA * Regent Pacific to receive a total payment of US$4 million upon the receipt of approval from the National Medical Products Administration (NMPA) for conducting human trial * China is expected to be the single largest market for Sendstend™ UNITED STATES * The Phase II valid...
2020-11-17 22:09
3387
Russia is considered a highly trusted vaccine manufacturer and almost half of respondents in 11 countries are aware of Sputnik V, a YouGov poll shows
MOSCOW, Nov. 17, 2020 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), announces the results of a survey of more than 12,000 respondents in 11 countries on their attitude towards vaccination against coronavirus and their vaccine preferences. According to ...
2020-11-17 21:38
1124
Foxx Life Sciences Announces Opening of New Asia Headquarters in India
SALEM, New Hampshire, Nov. 17, 2020 /PRNewswire/ -- Foxx Life Sciences announced on Tuesday that it will open the new internationalAsia headquarters in Medchal,Hyderabad, India. The latest expansion comes with strong growth and performance inAsia and the continued expansion of Biopharmaceutical ...
2020-11-17 21:00
1067
Late-Breaking Study Results of the Supreme HT™ Healing-Targeted DES Demonstrated Equivalent Outcomes with Exceptional Safety
TIANJIN, China, Nov. 17, 2020 /PRNewswire/ -- SINOMED® today announced that Prof.Alexandra Lansky from the Yale School of Medicine, USA, presented data from its first inter-continental PIONEER III study comparing the safety and efficacy of the Supreme HT (Healing-Targeted) Drug-Eluting Stent, t...
2020-11-17 18:49
1869
Week's Top Stories
Most Reposted
Tan Xuguang: Enter South Korea, Full Focus on Business in the "Doorstep" Market
[Picked up by 330 media titles]
2024-06-16 19:38
Rising Through the Ranks: Giti Recorded as the Fastest-Growing Tire Brand in the World, and They Are Not Stopping There
[Picked up by 311 media titles]
2024-06-12 15:34
Broad-Based ETFs Unleashing Opportunities to Invest in China A-Shares Amid Market Recovery
[Picked up by 238 media titles]
2024-06-11 10:06
The Third Hong Kong Science Fair Gathers Creative Technologies of the Next Generation
[Picked up by 231 media titles]
2024-06-10 12:11
Forrester: APAC Tech Spend To Grow 7% Annually, Reaching US $876 Billion In 2027
[Picked up by 224 media titles]
2024-06-11 12:07Most Read
Rising Through the Ranks: Giti Recorded as the Fastest-Growing Tire Brand in the World, and They Are Not Stopping There
2024-06-12 15:34
13175
Broad-Based ETFs Unleashing Opportunities to Invest in China A-Shares Amid Market Recovery
2024-06-11 10:06
11700
Chengdu's influence being felt across the world
2024-06-11 16:44
7800
Global Civilization Initiative conforms to trend, meets demand of times
2024-06-13 17:54
7687
